tbuckley/cabot-search huggingface dataset:
GE-12 * RADIOGRAPHICALLY-LOCALIZED BIOPSIES REVEAL SUBTYPE-SPECIFIC PATTERNS IN MOLECULAR AND CELLULAR COMPOSITION AT THE INFILTRATIVE MARGINS OF GLIOBLASTOMA
Authors: B. Gill, D. Pisapia, H. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, M. Banu, A. Dovas, J. Sims, A. Teich, S. Sheth, G. McKhann, M. Sisti, J. Bruce, P. Sims, P. Canoll
Journal: Neuro-Oncology (2014)

Glioblastomas (GBMs) diffusely infiltrate the brain, making complete removal by surgical resection impossible. The mixture of neoplastic and non-neoplastic cells that remain after surgery form the biological context for adjuvant therapeutic intervention and recurrence. We performed RNA-Seq and histological analysis on radiographically guided biopsies taken from different regions of GBM and showed that the tissue contained within the contrast-enhancing (CE) core of tumors have different cellular and molecular compositions compared to tissue from the non-enhancing (NE) margins of tumors. Comparisons with the TCGA dataset showed that the samples from CE regions resembled the Proneural, Classical, or Mesenchymal subtypes of GBM, while the samples from the NE regions predominantly resembled the Neural subtype. Computational deconvolution of the RNA-seq data revealed that contributions from non-neoplastic brain cells significantly influence the expression pattern in the NE samples. Gene ontology showed that the cell type-specific expression patterns were functionally distinct and highly enriched in genes associated with the corresponding cell phenotypes. Comparing the RNA-Seq data from the GBM samples to that of normal brain revealed that the differentially expressed genes are distributed across multiple cell types. Notably, the patterns of cell type-specific alterations varied between the different GBM subtypes; the NE regions of Proneural tumors were enriched in oligodendrocyte progenitor genes while the NE regions of Mesenchymal GBM were enriched in astrocytic and microglial genes. These subtype-specific patterns in the molecular and cellular composition of the infiltrative margins of GBM make it possible to infer key characteristics of the tissue left behind after surgery.
Weekly paclitaxel improved pathological response of primary chemotherapy compared with standard 3 weeks schedule.
Authors: T Ouyang, J Li, Y Xie, A Lu, B Li
Journal: Cancer Research (2009)

Abstract Abstract #5109 Background: Weekly paclitaxel is superior to every-3-wk schedule in the management of MBC. This single institute, prospective randomized trial was designed to compare the efficacy of the weekly paclitaxel to every-3-wk schedule in terms of pathological response.&amp;#x2028; Material and methods: Histologically confirmed T1-3 N0-1M0 invasive breast cancer pts planed to receive adjuvant chemotherapy were eligible. After the completion of 2 cycles of CTFci ( CTX 500mg/m2 d1/d8, pirarubicin 35 mg/m2 d1/d8, 5-Fu 200 mg/m2.day.ci d1-28, every 4 weeks) primary chemotherapy, pts were randomized to received 4 cycles of PTq3w (arm A: carboplatin AUC 6mg/ml.min day1, paclitaxel 175mg/m2 day1, every 3 weeks) or PTq1w (arm B: carboplatin AUC 6mg/ml.min day1, paclitaxel 60mg/m2 day1/8/15, every 3 weeks) before surgery, stratified by clinical response to 2 cycles of CTFci. Status of axillary node were determined by sentinel node biopsy or ultrasound guided FNA (if abnormal ultrasonographically) before primary chemotherapy. Pathological response of the primary tumor was evaluated by using Miller and Payne system, clinical response was determined by ultrasonography.&amp;#x2028; Results: From 05/2005 to 10/2007, 220 pts ( 196 were planed) under 65yr entered in this trial. 201 pts completed planed treatment and 12 pts(arm A 4 pts, arm B 8 pts)choice to have surgery after 2 cycles of paclitaxel treatment, other 7 pts (5 protocol violation, 1 without surgery, 1 treated in other hospital) were excluded for analysis. Clinical tumor status, node status, estrogen receptor expression, Her-2 expression and clinical response to CTFci were no different between two arms.&amp;#x2028; &amp;#x2028; Arm A resulted more G1/G2(loss of tumor cells less than 30%) and less G5/G4 ( loss of tumor cells more than 90%) than arm B (28.70% vs. 14.28% p=0.011, 44.44% vs. 58.10% p= 0.047 ). The pCR rate of positive node were 39.29%(11/28) in arm A and 54.17%(13/24) in arm B ( p=0.283).&amp;#x2028; &amp;#x2028; There were 17(15.74%) pts in arm A and 67(61.81%)pts in arm B experienced treatment delay caused by neutropenia(G3), thrombocytopenia(G2), anemia(G2) or hepatotoxicity(G2). There was no treatment related death.&amp;#x2028; Conclusion: Weekly paclitaxel was well tolerant and more effective than 3 week schedule. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5109.
AB0638 Metabolic syndrome characteristics in patients with primary gout
Authors: M. M. Radak-Perovic, M. I. Zlatkovic-Svenda, M. M. Zlatanovic, M. M. Sefik-Bukilica, M. M. Terek, T. V. Radnic-Zivanovic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The association between gout and obesity, dyslipidaemia, hypertension and hyperglycaemia is a well-known fact. The presence of most of these abnormalities in the same patient is termed as metabolic syndrome (MetS). MetS increases the risk and the mortality of atherosclerotic cardiovasular diseases (CVDs). In patients with gout the prevalence of MetS is 30% to 82%. <h3>Objectives</h3> To determine the prevalence of MetS and to examine the association between non-abdominal/abdominal obesity and the components of MetS in patients with primary gout. BMI/ waist circumference (WC) are anthropometric measurements used as indices of total and abdominal obesity. <h3>Methods</h3> A total of 81 pts with primary (ACR) gout, 95.1% males, underwent physical examination and blood tests. The original National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III were used to define MetS. Patients with three or more of the following criteria were defined as having MetS: abdominal obesity (WC≥102cm for men; ≥88cm for women), high TG (≥1,69mmol/L), low HDL(&lt;1, o4mmol/L for men, and &lt;1,29mmol/L for women), high blood pressure (≥135/85mmHg) and high fasting glucosae (≥6,1mmol/L). Patients currently taking antihypertensive or hypoglycaemic drugs met the criteria for high blood pressure or high FG. According to WHO, obesity was defined as BMI of ≥ 30kg/m2. <h3>Results</h3> The frequency of the individual items of MetS were: WC ≥102cm, 33 (40.7%); blood pressure ≥135/85 mmHg, 61 (75.3%); glucosae≥ 6,1, 32 (39.5%); HDL &lt;1,04mmol/l, 36 (44.4%); triglicerydes ≥1,69, 48 (59.3%). The BMI ≥30kg/m2 was found in 20(28.4%). The prevalence of MetS in pts with gout was 56.8% and it increased with age (from 48.7% in pts younger than 60 years to 64.3% in pts aged 60 and more). Subjects with MetS had higher SUA and sera creatinin leveles than those without MetS, but without statistically significant difference. BMI positively correlated with HTA and hypercholesterolemia (p=0.015 and p=0.041, respectively), and WC positively correlated with HTA (p=0.003). <b>Conclusions: 1.</b>Our data has shown high prevalence of MetS among gouty pts <b>2.</b>Correlations between BMI and the components of MetS were similar to those of WC implicating the appropriateness of using either of antropometric measures as indices of obesity in clinical practice <b>3</b>. Management of obesity should be emphasized to correct metabolic abnormalities in gouty patients. <h3>Disclosure of Interest</h3> None Declared
Easy-to-Use Online Software Package for Internal Dose Assessment After Radionuclide Treatment in Clinical Routine
Authors: Siroos Mirzaei, Antti Sohlberg, Peter Knoll, Rasoul Zakavi, Markus Diemling
Journal: Clinical Nuclear Medicine (2013)

Background Internal dose assessment after radionuclide therapy is usually performed using home-made software packages. The dose assessment includes image registration, region-of-interest drawing, time-activity curve generation, and manual calculation of residence times followed by dose calculation with the OLINDA/MIRD software. The drawback of these methods is that several steps have to be performed using various software products possibly installed on different workstations. The aforementioned approaches are error-prone as well as difficult and time-consuming. In this article, we present a commercial software package that implements all the required dose calculation steps in 1 application, which greatly facilitates the internal dose assessment. Methods and Results The workflow of the newly developed software package "Hybrid Dosimetry" proceeds from automatic image registration to region-of-interest drawing, followed by time-activity curve fitting and dose calculation according to the MIRD method. The software is available online and can be run on independent computers using images in the common DICOM format. We used the package for internal dosimetry of 8 patients treated with 177Lu-DOTATATE and compared the results with manual dose calculation. Conclusions The online software package presented is platform independent and allows fast dose calculations. The results obtained with the new package were in perfect agreement with manual methods.
An unusual case of recurrent hepatocellular carcinoma presenting as an indeterminate right intrahepatic duct stricture
Authors: Tiing Ang, Andrew Kwek, Wee Poh
Journal: Endoscopy (2016)

A 46-year-old man with segment 8 hepatocellular carcinoma (HCC) from hepatitis C-related, Child–Pugh class A cirrhosis underwent successful hepatic resection. This was complicated by a postoperative bilioma that was treated by percutaneous drainage. He presented again 6 months later with abdominal pain and cholestasis. Computed tomography (CT) of the liver showed no tumor recurrence. Magnetic resonance imaging (MRI) showed post-cholecystectomy status, a mildly dilated common bile duct, non-visualization of the central right intrahepatic duct, a focal defect in the left intrahepatic duct, and proximal dilatation of both intrahepatic ducts ([Fig. 1]). Cholangioscopy using the SpyGlass DS Direct Visualization System (Boston Scientific, Natick, Massachusetts, USA) was performed. Blood clots were visualized in the left intrahepatic duct. A friable mass was visualized in the right intrahepatic duct ([Fig. 2]) and was biopsied ([Video 1]). Bilateral stenting was performed. Histology revealed recurrent HCC ([Fig. 3]).
THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS
Authors: Muthiah Vaduganathan, Robert Harrington, Gregg Stone, Philippe Steg, C. Michael Gibson, Christian Hamm, Matthew Price, Alberto Menozzi, Jayne Prats, Efthymios Deliargyris, Kenneth Mahaffey, Harvey White, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2016)
Floating Right Atrial Thrombus and Massive Pulmonary Embolism
Authors: A Baumbach, C M Erley
Journal: New England Journal of Medicine (1998)

Figure 1. Four weeks after undergoing surgery to remove an intraventricular meningioma, a 64-year-old woman had recurrent episodes of dyspnea and hypotension. Ultrasonography revealed a deep venous thrombosis involving the left popliteal vein. Treatment with heparin and dobutamine was started, and the patient was transferred to our hospital. On admission, she had severe dyspnea, a blood pressure of 110/80 mm Hg, and a pulse of 105 beats per minute. Arterial-blood gas analysis obtained while the patient was breathing 100 percent oxygen showed a partial pressure of oxygen of 88 mm Hg and a partial pressure of carbon dioxide of 32 . . .
The Systemic Amyloidoses
Authors: Rodney H. Falk, Raymond L. Comenzo, Martha Skinner
Journal: New England Journal of Medicine (1997)

Amyloidosis is not a single disease but a term for diseases that share a common feature: the extracellular deposition of pathologic insoluble fibrillar proteins in organs and tissues. In the mid-19th century, Virchow adopted the botanical term "amyloid," meaning starch or cellulose, to describe abnormal extracellular material seen in the liver at autopsy.1 Subsequently, amyloid was found to stain with Congo red, appearing red microscopically in normal light but apple green when viewed in polarized light.2,3 Almost a century after Virchow's observations, the fibrillar nature of amyloid was described with the use of electron microscopy and the characteristic beta-pleated–sheet . . .
Cold Spring Harbor Symposia: Time Capsule of Cancer Research
Authors: M. E. Newman
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Cold Spring Harbor Symposia: Time Capsule of Cancer Research Get access Michael E. Newman Michael E. Newman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 2, 16 January 1991, Page 86, https://doi.org/10.1093/jnci/83.2.86 Published: 16 January 1991
PM-03 * ROLE OF Olig2 PHOSPHORYLATION IN PEDIATRIC GLIOMA FORMATION
Authors: A. Griveau, A.-C. Tien, D. H. Rowitch
Journal: Neuro-Oncology (2014)

Malignant gliomas are a leading cause of tumor-related mortality in children. Current therapies often have significant adverse effects on brain development and are largely ineffective against aggressive gliomas. The development of rational therapies has been limited by poor information regarding the cell of origin for pediatric glioma and the relevant underlying genetic alterations. Recent findings now reveal that mutations existing in pediatric glioma are different than those seen in adult gliomas. For example, BRAFV600E activating mutations are associated with deletion of the tumor suppressor gene, p16 (Ink4a-Arf), in about 15% of pediatric gliomas. We have generated a faithful genetic mouse model in which there is concomitant activation of BRAFV600E and deletion of Ink4a-Arf in oligodendrocyte progenitor cells (OPCs) leading to the generation of pediatric high-grade glioma. OPCs have been shown to be a potential cell of origin for glioma and expression of Olig2 is found in 100 percent of human pediatric and adult high-grade gliomas. Given that Olig2 is also required for normal myelin development, targeting all Olig2-expressing cells with small molecule inhibitors would likely have detrimental effects. We have recently found that Olig2 protein is present in a phosphorylated form that promotes proliferation of adult glioma cells. In this study, we demonstrate that phospho-Olig2 is expressed in tumorigenic oligodendrocyte progenitor cells and is required for pediatric glioma generation. In addition, we found that phospho-Olig2 and Olig2 interact with different proteins, some of which are feasible drug targets. This study gives insights into new therapies by understanding key protein interactions in normal oligodendrocyte development as well as in tumorigenic oligodendrocyte progenitor cells.
Mitochondrial Metabolic Reprogramming of Melanoma Cells Exposed to BRAFV600E Inhibitor
Authors: J. Kluza, M. Jendoubi, P. Corazao-Rozas, F. André, A. Jonneaux, P. Guerreschi, P. Formstecher, L. Mortier, P.H.I. Marchetti
Journal: Annals of Oncology (2013)
Pathogenesis of Hypokalemic Alkalosis in Cushing's Syndrome
Authors: Nicholas P. Christy, John H. Laragh
Journal: New England Journal of Medicine (1961)

HYPOKALEMIC alkalosis has been variously reported as common2 , 3 and rare4 in Cushing's syndrome. Plotz, Knowlton and Ragan5 reported 4 cases of severe hypokalemia in 31 patients with this disease. Bagshawe4 and Allott and Skelton6 pointed out the concurrence of Cushing's syndrome, hypokalemia and neoplasms of extra-adrenal origin, and Bagshawe7 described the association of severe hypokalemic alkalosis with adrenal metastases from primary tumors of the bronchus and prostate.At least three hormonal mechanisms might be invoked to explain the electrolyte disturbance. These are excessive adrenocortical secretion of aldosterone, Cortisol or mineralocorticoids that are not secreted in large amounts under normal conditions . . .
Abstract 2584: The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA
Authors: Li Peng, Michael Oberst, Jiaqi Huang, Philip Brohawn, Kristen Lekstrom, Maria Amann, Patrick Baeuerle, Bahija Jallal, Pamela Trail, Herren Wu, Yihong Yao, Steven Coats, William Dall”Acqua, Melissa Damschroder, Scott A. Hammond
Journal: Cancer Research (2010)

Abstract MEDI-565 (MT111) is a novel bispecific single-chain antibody of the BiTE (Bi-specific T-cell engager) class that transiently links carcinoembryonic antigen (CEA) on tumor cells with human CD3 on T cells. Engagement of CD3 and CEA by MEDI-565 induces T cells to kill CEA-positive cancer cells using similar elements and cellular machinery as required for T cells to kill through classic T cell receptor/major histocompatibility complex-peptide signaling. Examination of DNA sequence databases revealed a canonical CEA sequence (full length CEA; NCBI RefSeq NP_004354.2; 702 amino acids) and a previously uncharacterized shorter mRNA splice variant (short CEA; NCBI RefSeq CR749337420 amino acids) that lacks the second and third IgC-like domains and part of the N-terminal IgV-like domain. Expression of full-length CEA mRNA in colorectal, pancreatic, lung, and breast tumors was more widespread than that of short CEA; however, concordant expression of short CEA with the full length version was always observed. Mapping of the MEDI-565 binding region of CEA revealed a nonlinear, conformational epitope in the third immunoglobulin C-like domain. With a combination of deletion and swap variants, site directed mutagenesis, and computational homology modeling, we further identified the critical residues for MEDI-565 binding comprised of Phe292, Thr294, Asn299, Val354, Gly355, Pro356, Glu358, Ile374, and Asn376. CHO cells expressing only the short variant of CEA lacking this epitope failed to bind MEDI-565 and did not undergo T cell-directed lysis in the presence of MEDI-565. These studies suggest that MEDI-565 can discriminate between the full-length and short splice variant of CEA and may broadly target CEA-positive colorectal, pancreatic, lung, and breast tumors without regard for expression of the short splice variant of CEA. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2584.
OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months
Authors: B. Terrier, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaitre, P. Cohen, F. Maurier, O. Decaux, H. Demurs-Clavel, P. Gobert, T. Quemeneur, P. Godmer, X. Puechal, L. Mouthon, L. Guillevin
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The prospective, randomized, controlled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) to maintain ANCA-associated vasculitis (AAV) remission. Once remission was obtained with a conventional regimen, patients were randomly assigned to receive a 500-mg RTX infusion on D1, D15, 5.5 months later, then every 6 months for a total of 5 infusions over 18 months, or AZA for 22 months at the initial dose of 2 mg/kg/d. The primary endpoint was the major relapse rate (EULAR/ACR criteria) at 28 months. This study demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated vasculitis (AAV) remission during the 28-month follow-up, with a similar profile of tolerance. <h3>Objectives</h3> This study describes the extended follow-up of patients included in the MAINRITSAN trial. <h3>Methods</h3> Extended follow-up was ascertained from the patients included in the trial. Data on relapse and survival were collected from physician records. All patients were analyzed according to the group to which they were randomized. <h3>Results</h3> Median duration of follow-up was 34.3 months (IQR, 28.7-39.6 months). Six out of 56 (10.7%) RTX patients and 24/53 (45.3%) AZA patients had at least one major relapse. The risk of major relapse remained significantly lower in the RTX-arm compared to the AZA-arm (hazard ratio 0.18, 95% CI 0.09 to 0.42, P&lt;0.0001). During follow-up, 4 patients died in the AZA arm but none in the RTX arm. Overall survival rates was lower in the RTX-arm compared to the AZA-arm (P=0.037). <h3>Conclusions</h3> Despite relapses in the RTX-arm after the end of the study period, RTX remains associated with a lower risk of relapse than AZA. RTX is also associated with a better overall survival compared to AZA. <h3>Disclosure of Interest</h3> None Declared
Hepatitis B Virus rtI233V Mutation and Resistance to Adefovir
Authors: Andreas Geipel, Dieter Glebe, Hans Will, Wolfram H Gerlich
Journal: New England Journal of Medicine (2014)

In a 2006 Journal article, adefovir resistance in three patients with HBV infection was attributed to a rare mutation, rtI233V. Two authors, along with two others, used new techniques to test samples from the patients and now conclude that the failure of adefovir was not caused by rtI233V.
<i>Candida tropicalis</i>as a Pathogen for Man
Authors: Ralph Richart, Gustave J. Dammin
Journal: New England Journal of Medicine (1960)

OVER 25 species of the genus candida have been identified on the basis of their morphologic, colonial and biochemical characteristics and their pathogenicity for man and animals. Candida albicans is the prototype of the pathogenic candida and is listed in most standard textbooks1 , 2 as the only member of the genus with pathogenicity for man. C. albicans, tropicalis, pseudotropicalis, krusei, parakrusei, stellatoidea and guilliermondi are the members of the genus commonly isolated from man.3 All have been found in routine cultures of nose, throat, skin, vagina and gastrointestinal tract and are usually regarded as saprophytes. They are often encountered in the . . .